MCID: CNT016
MIFTS: 49

Central Retinal Vein Occlusion

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Central Retinal Vein Occlusion

MalaCards integrated aliases for Central Retinal Vein Occlusion:

Name: Central Retinal Vein Occlusion 12 59 55 15 73
Crvo 59

Characteristics:

Orphanet epidemiological data:

59
central retinal vein occlusion
Prevalence: 1-5/10000 (Europe); Age of onset: Adult,Elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:2450
ICD10 33 H34.81
ICD9CM 35 362.35
NCIt 50 C118859
SNOMED-CT 68 193378003 68478007
Orphanet 59 ORPHA411527
UMLS via Orphanet 74 C0154841
ICD10 via Orphanet 34 H34.8
UMLS 73 C0154841

Summaries for Central Retinal Vein Occlusion

MalaCards based summary : Central Retinal Vein Occlusion, also known as crvo, is related to macular retinal edema and macular holes. An important gene associated with Central Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 The central retinal vein is the venous equivalent of the central retinal artery and, like that blood... more...

Related Diseases for Central Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Central Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 30.6 IL6 SERPINF1 VEGFA
2 macular holes 30.3 SERPINF1 VEGFA
3 factor xii deficiency 29.9 APOH F5 SERPINC1
4 purpura 29.9 APOH F2 SERPINC1
5 exfoliation syndrome 29.9 LOXL1 MTHFR
6 hemophilia b 29.8 F2 SERPINC1
7 arteritic anterior ischemic optic neuropathy 29.8 F2 F5 MTHFR
8 thrombocytosis 29.4 F2 IL6 SERPINC1
9 pulmonary hypertension 29.4 IL6 SERPINC1 VEGFA
10 branch retinal artery occlusion 29.3 APOH F2 MTHFR SERPINC1
11 von willebrand's disease 29.3 F2 F5
12 nonarteritic anterior ischemic optic neuropathy 29.2 F2 F5 MTHFR SERPINC1
13 protein c deficiency 29.0 F2 F5 MTHFR SERPINC1
14 eclampsia 29.0 F2 F5 MTHFR SERPINC1
15 retinal artery occlusion 29.0 APOH F2 F5 MTHFR SERPINC1
16 thrombophilia 28.9 APOH F2 F5 MTHFR SERPINC1
17 sneddon syndrome 28.9 APOH F2 F5 SERPINC1
18 ischemic optic neuropathy 28.8 APOH F2 F5 MTHFR SERPINC1
19 protein s deficiency 28.8 APOH F2 F5 MTHFR SERPINC1
20 thrombosis 28.5 APOH F2 F5 MTHFR SERPINC1
21 antithrombin iii deficiency 28.3 APOH F2 F5 MTHFR SERPINC1
22 antiphospholipid syndrome 28.3 APOH F2 F5 MTHFR SERPINC1
23 retinal vascular occlusion 27.7 APOH F2 F5 MTHFR SERPINC1 VEGFA
24 hellp syndrome 27.4 APOH F2 F5 IL6 MTHFR SERPINC1
25 vascular disease 26.7 APOH F2 F5 IL6 MTHFR SERPINC1
26 pre-eclampsia 26.7 APOH F2 F5 IL6 MTHFR SERPINC1
27 retinal vein occlusion 26.5 APOH F2 F5 IL6 LOXL1 MTHFR
28 retinitis 11.2
29 inferior vena cava interruption 10.7 F5 MTHFR
30 amaurosis fugax 10.7 F5 MTHFR
31 hemifacial spasm 10.7 MTHFR VEGFA
32 may-thurner syndrome 10.6 APOH F5
33 acanthamoeba keratitis 10.6 APOH F5
34 pregnancy loss, recurrent 1 10.6 APOH F5
35 sticky platelet syndrome 10.6 F5 SERPINC1
36 carotid artery occlusion 10.5 APOH F5
37 schizencephaly 10.5 F5 MTHFR
38 osteoporotic fracture 10.5 IL6 MTHFR
39 meningococcemia 10.5 F5 SERPINC1
40 endotheliitis 10.5
41 legg-calve-perthes disease 10.5 F5 SERPINC1
42 gastroschisis 10.5 IL6 MTHFR
43 acute hemorrhagic leukoencephalitis 10.5 SERPINC1 VEGFA
44 critical limb ischemia 10.5 IL6 VEGFA
45 encephalomalacia 10.4 IL6 MTHFR
46 spinal disease 10.4 IL6 VEGFA
47 chorioretinitis 10.4
48 poems syndrome 10.4 IL6 VEGFA
49 primary effusion lymphoma 10.4 IL6 VEGFA
50 mesenteric vascular occlusion 10.4 F2 MTHFR

Comorbidity relations with Central Retinal Vein Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Retinal Vein Occlusion:



Diseases related to Central Retinal Vein Occlusion

Symptoms & Phenotypes for Central Retinal Vein Occlusion

MGI Mouse Phenotypes related to Central Retinal Vein Occlusion:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.95 SERPINC1 F2 SERPINF1 F5 VEGFA IL6
2 homeostasis/metabolism MP:0005376 9.92 APOH SERPINC1 F2 F5 VEGFA IL6
3 digestive/alimentary MP:0005381 9.77 F2 SERPINF1 VEGFA IL6 LOXL1
4 nervous system MP:0003631 9.76 SERPINC1 F2 SERPINF1 F5 VEGFA IL6
5 integument MP:0010771 9.73 F2 F5 VEGFA IL6 LOXL1 MTHFR
6 reproductive system MP:0005389 9.5 SERPINC1 F2 SERPINF1 VEGFA IL6 LOXL1
7 vision/eye MP:0005391 9.02 MTHFR SERPINC1 SERPINF1 VEGFA IL6

Drugs & Therapeutics for Central Retinal Vein Occlusion

Drugs for Central Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 124-94-7 31307
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-02-2 5743
4
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
5
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
6
Lactitol Investigational Phase 4 585-86-4 3871
7 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
19 Mitogens Phase 4,Phase 3,Phase 1,Phase 2
20 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
21 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
22 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
23 BB 1101 Phase 4,Phase 2,Phase 3,Not Applicable
24 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Not Applicable 1177-87-3
25 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
28
protease inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
29 Dexamethasone 21-phosphate Phase 4
30 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31
Povidone-iodine Approved Phase 3,Not Applicable 25655-41-8
32
Iodine Approved, Investigational Phase 3 7553-56-2 807
33
Povidone Approved Phase 3 9003-39-8
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
35
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 59-67-6 938
36
Nicotinamide Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 98-92-0 936
37 Anticholesteremic Agents Phase 3
38 Antimetabolites Phase 3,Phase 2
39 Atorvastatin Calcium Phase 3 134523-03-8
40 Calcium, Dietary Phase 3
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
42 Hypolipidemic Agents Phase 3,Phase 2
43 Lipid Regulating Agents Phase 3,Phase 2
44 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable
45 Antibiotics, Antitubercular Phase 3,Not Applicable
46 Micronutrients Phase 2, Phase 3
47 Nicotinic Acids Phase 2, Phase 3
48 Ophthalmic Solutions Phase 2, Phase 3,Phase 1
49 Tetrahydrozoline Phase 2, Phase 3
50 Trace Elements Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
3 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
4 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
5 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
6 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4 ranibizumab
7 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
8 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
9 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
10 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
11 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
12 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed NCT02503540 Phase 4 Aflibercept
13 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Active, not recruiting NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
14 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Active, not recruiting NCT02274259 Phase 4 Aflibercept;Ranibizumab
15 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
16 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
17 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT00943072 Phase 3 Sham
18 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
19 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3 Active bevacizumab and Sham dexamethasone;Active bevacizumab and Active dexamethasone
20 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT01535261 Phase 3 Ranibizumab 0.5 mg/0.05 ml
21 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
22 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01396083 Phase 3 Ranibizumab;Dexamethasone implant and sham injections
23 A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) Completed NCT00485836 Phase 3 Sham injection;Ranibizumab injection 0.3 mg;Ranibizumab injection 0.5 mg
24 The ROVO Study: Radial Optic Neurotomy for CVO Completed NCT00532142 Phase 2, Phase 3 Intravitreal Triamcinolone
25 A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO Completed NCT00567697 Phase 3 ranibizumab;ranibizumab
26 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3 ranibizumab
27 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
28 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3 ranibizumab
29 Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions Completed NCT00500045 Phase 2, Phase 3 nicotinic acid
30 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
31 Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage Completed NCT00106132 Phase 3 Triamcinolone Acetonide
32 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
33 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3 dexamethasone implant
34 Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Recruiting NCT03223714 Phase 3 Conbercept Ophthalmic Injection;sham injection
35 DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME Recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
36 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Active, not recruiting NCT01969708 Phase 3 aflibercept;bevacizumab
37 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
38 Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Unknown status NCT02405741 Phase 2
39 Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) Unknown status NCT01178697 Phase 2 Bevasizumab;Triamcinolone Acetonide
40 Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT01123564 Phase 2 ranibizumab
41 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
42 Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion Completed NCT02614937 Phase 1, Phase 2 ranibizumab;Squalamine Lactate Ophthalmic Solution, 0.2%
43 Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Completed NCT01724554 Phase 1, Phase 2 Intravitreal Aflibercept Injection
44 Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT00088283 Phase 2 pegaptanib sodium
45 Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Completed NCT01471691 Phase 1, Phase 2 ranibizumab 0.5mg;ranibizumab 1.0mg
46 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
47 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
48 Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions Completed NCT01003106 Phase 1, Phase 2 Ranibizumab 0.5mg (monthly);Ranibizumab 2.0mg (monthly);Pro re nata (prn) ranibizumab
49 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Recruiting NCT02957760 Phase 2 Hydroxycarbamid
50 Minocycline to Treat Central Retinal Vein Occlusion Recruiting NCT01468844 Phase 1, Phase 2 Minocycline

Search NIH Clinical Center for Central Retinal Vein Occlusion

Genetic Tests for Central Retinal Vein Occlusion

Anatomical Context for Central Retinal Vein Occlusion

MalaCards organs/tissues related to Central Retinal Vein Occlusion:

41
Eye, Retina, Endothelial, Bone, Myeloid, Colon, Liver

Publications for Central Retinal Vein Occlusion

Articles related to Central Retinal Vein Occlusion:

(show top 50) (show all 686)
# Title Authors Year
1
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
2
Effects of Dexamethasone Implant on Multifocal Electroretinography in Central Retinal Vein Occlusion. ( 29403585 )
2018
3
YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey. ( 29364731 )
2018
4
USE OF THE ISCHEMIC INDEX ON WIDEFIELD FLUORESCEIN ANGIOGRAPHY TO CHARACTERIZE A CENTRAL RETINAL VEIN OCCLUSION AS ISCHEMIC OR NONISCHEMIC. ( 29474305 )
2018
5
Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema. ( 29804112 )
2018
6
Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report. ( 29505511 )
2018
7
Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion. ( 29572586 )
2018
8
INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial. ( 29624543 )
2018
9
The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. ( 29550932 )
2018
10
Sequential Observations of Conversion from Nonischemic to Ischemic Central Retinal Vein Occlusion Using Optical Coherence Tomography Angiography. ( 29850324 )
2018
11
Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. ( 29185099 )
2018
12
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. ( 29632703 )
2018
13
Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. ( 29447089 )
2018
14
Swept-Source OCT Angiographic Imaging of a Central Retinal Vein Occlusion During Pregnancy. ( 29554389 )
2018
15
Anomalous coagulation factors in non-arteritic anterior ischemic optic neuropathy with central retinal vein occlusion: A case report. ( 29642215 )
2018
16
Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion. ( 29487816 )
2018
17
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. ( 29426292 )
2018
18
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study. ( 28744657 )
2017
19
Central Retinal Vein Occlusion-like Appearance: A Precursor Stage in Evolution of Frosted Branch Angiitis. ( 29090058 )
2017
20
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. ( 28492910 )
2017
21
Unilateral Adult Xanthogranulomatous Infiltration of the Conjunctiva, Limbus and Sclera Leading to a Combined Ophthalmic Artery and Central Retinal Vein Occlusion. ( 29299083 )
2017
22
Cilioretinal Artery Occlusion Combined with Central Retinal Vein Occlusion: What Is the Best Imaging Modality for the Follow-Up? ( 29430314 )
2017
23
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion. ( 28591282 )
2017
24
LABORATORY EVALUATION OF HYPERCOAGULABLE STATES IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION WHO ARE LESS THAN 56 YEARS OF AGE. ( 28613222 )
2017
25
EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. ( 28767552 )
2017
26
BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. ( 28538263 )
2017
27
Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial. ( 28979743 )
2017
28
Central retinal vein occlusion after coronary artery bypass surgery: A case report. ( 28605930 )
2017
29
"Dye front reciprocation" in combined central retinal vein occlusion with cilioretinal artery infarction. ( 29133654 )
2017
30
Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion. ( 28739419 )
2017
31
Predictive Value of Baseline Biochemical Parameters for Clinical Response of Macular Edema to Bevacizumab in Eyes With Central Retinal Vein Occlusion: A Retrospective Analysis. ( 29082677 )
2017
32
CONN SYNDROME PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION. ( 28644176 )
2017
33
Management of macular edema due to central retinal vein occlusion - The role of aflibercept. ( 29018760 )
2017
34
RETINAL MICROVASCULATURE AND VISUAL ACUITY AFTER INTRAVITREAL AFLIBERCEPT IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. ( 28902097 )
2017
35
BARTONELLA HENSELAE NEURORETINITIS ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION, CHOROIDAL ISCHEMIA, AND ISCHEMIC OPTIC NEUROPATHY. ( 28700390 )
2017
36
EVALUATION OF MACULAR ISCHEMIA IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. ( 28671896 )
2017
37
Treatment of Macular Edema Due to Central Retinal Vein Occlusion: Another Score for Repackaged Bevacizumab. ( 28492939 )
2017
38
Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion. ( 28803326 )
2017
39
High Altitude Retinopathy Presenting as Central Retinal Vein Occlusion in a Soldier. ( 29185408 )
2017
40
Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. ( 28946138 )
2017
41
Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature. ( 28603574 )
2017
42
Metamorphopsia associated with central retinal vein occlusion. ( 29049410 )
2017
43
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: special remarks of the RANIDEX study. ( 28752369 )
2017
44
A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial. ( 28302155 )
2017
45
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. ( 28620704 )
2017
46
Central Retinal Vein Occlusion in 2 Patients Using Antipsychotic Drugs. ( 28924438 )
2017
47
Assessment of ischemia in acute central retinal vein occlusion from inner retinal reflectivity on spectral domain optical coherence tomography. ( 28053503 )
2017
48
One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion. ( 29260119 )
2017
49
EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data. ( 27548351 )
2016
50
Central retinal vein occlusion associated with high blood levels of lipoprotein (a).: Is lipoprotein (a) a reliable marker for identification of predisposed individuals? ( 28003785 )
2016

Variations for Central Retinal Vein Occlusion

Expression for Central Retinal Vein Occlusion

Search GEO for disease gene expression data for Central Retinal Vein Occlusion.

Pathways for Central Retinal Vein Occlusion

GO Terms for Central Retinal Vein Occlusion

Cellular components related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 APOH F2 F5 IL6 LOXL1 SERPINC1
2 endoplasmic reticulum lumen GO:0005788 9.46 F2 F5 IL6 SERPINC1
3 extracellular matrix GO:0031012 9.43 APOH LOXL1 SERPINF1
4 extracellular space GO:0005615 9.23 APOH F2 F5 IL6 LOXL1 SERPINC1

Biological processes related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.65 F2 F5 SERPINC1
2 lactation GO:0007595 9.52 SERPINC1 VEGFA
3 blood circulation GO:0008015 9.51 F5 MTHFR
4 platelet degranulation GO:0002576 9.5 APOH F5 VEGFA
5 acute-phase response GO:0006953 9.49 F2 IL6
6 positive regulation of JAK-STAT cascade GO:0046427 9.46 F2 IL6
7 negative regulation of endothelial cell migration GO:0010596 9.43 APOH SERPINF1
8 blood coagulation, intrinsic pathway GO:0007597 9.4 APOH F2
9 positive regulation of blood coagulation GO:0030194 9.37 APOH F2
10 hemostasis GO:0007599 9.33 F2 F5 SERPINC1
11 negative regulation of fibrinolysis GO:0051918 9.26 APOH F2
12 cellular protein metabolic process GO:0044267 9.26 F2 F5 IL6 SERPINC1
13 regulation of blood coagulation GO:0030193 8.8 APOH F2 SERPINC1

Molecular functions related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 F2 IL6 VEGFA
2 heparin binding GO:0008201 8.92 APOH F2 SERPINC1 VEGFA

Sources for Central Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....